G
Gilead Sciences
Gilead Sciences agreed to a $246.75 million settlement for direct purchasers of HIV drugs Truvada, Atripla, and generics who paid too much.
ClosedUnited States-wideClaim status: Closed on January 1, 2024Payout: TBDNo longer claimable
About this settlement
A class action settlement for direct purchasers alleging overpayment for certain HIV drugs manufactured by Gilead Sciences.
This settlement resolves claims that Gilead Sciences overcharged direct purchasers of HIV drugs Truvada, Atripla, and their generic equivalents. Eligible entities who bought these drugs directly from manufacturers between February 2018 and September 2022 may submit claims for compensation.
Who qualifies
- Entities that purchased Truvada, Atripla, or their generic equivalents directly from a manufacturer.
- Purchases made between February 1, 2018 and September 27, 2022.
TBD
Claim status: Closed on January 1, 2024